PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1998716
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1998716
Prostate-Specific Antigen Test Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026 - 2035
The Global Prostate-Specific Antigen Test Market was valued at USD 5.1 billion in 2025 and is estimated to grow at a CAGR of 7.1% to reach USD 10.1 billion by 2035.
No image found before the marker.The market's expansion is fueled by the increasing prevalence of prostate cancer, ongoing technological advancements in PSA testing, and the growth of diagnostic laboratory infrastructure worldwide. PSA tests measure the level of a protein produced by the prostate gland, aiding in the early detection of prostate cancer, monitoring disease progression, and assessing treatment outcomes. Technological innovations, such as high-sensitivity assays, automated immunoassay systems, and improved test accuracy, have strengthened clinical confidence in PSA testing. Additional methods, including PSA density, PSA velocity, and reflex testing, enhance diagnostic precision, supporting broader clinical adoption. The industry is moving toward risk-based screening strategies, integrating PSA testing with advanced diagnostic workflows to balance early detection with minimizing overdiagnosis. Factors such as age, ethnicity, family history, baseline PSA levels, and comorbidities increasingly guide testing decisions, making PSA testing more targeted and therapeutically relevant.
The preliminary tests segment held 68% share in 2025 owing to its widespread use as an initial screening tool. Total PSA, free PSA ratio, and first-line screening panels are commonly employed to evaluate cancer risk before recommending invasive procedures. These tests are cost-effective, accessible, and non-invasive, helping clinicians stratify patients and avoid unnecessary biopsies, thereby supporting safer clinical decisions.
| Market Scope | |
|---|---|
| Start Year | 2025 |
| Forecast Year | 2026-2035 |
| Start Value | $5.1 Billion |
| Forecast Value | $10.1 Billion |
| CAGR | 7.1% |
The prostate cancer screening segment held a 53.5% share in 2025 and is projected to reach USD 5.1 billion through 2035. PSA testing continues to play a crucial role in early detection, particularly in aging populations, driving its adoption in both targeted and population-based screening programs. Government and institutional support in organized screening initiatives reduces financial and logistical barriers, further increasing test uptake.
North America Prostate-Specific Antigen Test Market accounted for 36.9% share in 2025, driven by the high incidence of prostate cancer, an aging male population, and strong awareness of early detection. Hospitals, specialty clinics, and diagnostic laboratories routinely incorporate PSA testing into standard screening programs. Advanced healthcare infrastructure, including state-of-the-art laboratories and point-of-care facilities, along with high investment in next-generation assays, facilitates rapid adoption and widespread availability of PSA tests in the region.
Key players in the Global Prostate-Specific Antigen Test Market include Abbott, AdvaCare Pharma, Beckman Coulter, BIOMERIEUX, CTK Biotech, DiaSorin, Fujirebio, Intec, KOELIS, Labcorp, mdxhealth, Myriad Genetics, OPKO Health, Roche, and SIEMENS Healthineers. Companies in the Global Prostate-Specific Antigen Test Market are employing multiple strategies to strengthen their market foothold. They focus on product innovation, developing highly sensitive, automated, and user-friendly assays for accurate early detection and monitoring. Strategic partnerships with hospitals, diagnostic labs, and healthcare networks expand distribution and adoption. Investment in R&D ensures next-generation technologies, improved assay performance, and regulatory compliance. Geographic expansion into high-growth regions increases market penetration, while marketing campaigns emphasize accuracy, reliability, and clinical relevance. Firms also provide training and technical support to laboratories and clinicians to enhance usage and build long-term customer loyalty, thereby solidifying their competitive positioning.
Table of Contents
Chapter 1 Research Methodology
- 1.1 Research approach
- 1.2 Quality commitments
- 1.2.1 GMI AI policy & data integrity commitment
- 1.2.1.1 Source consistency protocol
- 1.2.1 GMI AI policy & data integrity commitment
- 1.3 Research trail & confidence scoring
- 1.3.1 Research trail components
- 1.3.2 Scoring components
- 1.4 Data collection
- 1.4.1 Partial list of primary sources
- 1.5 Data mining sources
- 1.5.1 Paid sources
- 1.5.1.1 Sources, by region
- 1.5.1 Paid sources
- 1.6 Base estimates and calculations
- 1.6.1 Base year calculation for any one approach
- 1.7 Forecast model
- 1.7.1 Quantified market impact analysis
- 1.7.1.1 Mathematical impact of growth parameters on forecast
- 1.7.1 Quantified market impact analysis
- 1.8 Research transparency addendum
- 1.8.1 Source attribution framework
- 1.8.2 Quality assurance metrics
- 1.8.3 Our commitment to trust
Chapter 2 Executive Summary
- 2.1 Industry 3600 synopsis
- 2.2 Key market trends
- 2.2.1 Regional trends
- 2.2.2 Product trends
- 2.2.3 Application trends
- 2.2.4 End use trends
- 2.3 CXO perspectives: Strategic imperatives
- 2.3.1 Key decision points for industry executives
- 2.3.2 Critical success factors for market players
- 2.4 Future outlook and strategic recommendations
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing incidence of prostate cancer
- 3.2.1.2 Adoption of personalized healthcare and preventive diagnostics
- 3.2.1.3 Technological advancements in diagnostic assays and point-of-care testing
- 3.2.1.4 Rising awareness of early detection and screening
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 High cost of advanced PSA testing technologies
- 3.2.2.2 Limited specificity and false positives leading to overdiagnosis
- 3.2.3 Market opportunities
- 3.2.3.1 Development of next-generation and multi-marker diagnostic platforms
- 3.2.3.2 Growth in home-based and decentralized testing solutions
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.4.1 North America
- 3.4.2 Europe
- 3.4.3 Asia Pacific
- 3.5 Technology landscape
- 3.5.1 Current technological trends
- 3.5.2 Emerging technologies
- 3.6 Reimbursement scenario
- 3.7 Future market trends
- 3.8 Pricing analysis, 2025
- 3.9 Porter's analysis
- 3.10 PESTEL analysis
- 3.11 Customer insights
- 3.12 Start-up scenarios
- 3.13 Investment landscape
- 3.14 Gap analysis
Chapter 4 Competitive Landscape, 2025
- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Company market share analysis
- 4.3.1 Global
- 4.3.2 North America
- 4.3.3 Europe
- 4.3.4 Asia Pacific
- 4.4 Competitive positioning matrix
- 4.5 Competitive analysis of major market players
- 4.6 Key developments
- 4.6.1 Mergers & acquisitions
- 4.6.2 Partnerships & collaborations
- 4.6.3 New product launches
- 4.6.4 Expansion plans
Chapter 5 Market Estimates and Forecast, By Product, 2022 - 2035 ($ Mn)
- 5.1 Key trends
- 5.2 Preliminary tests
- 5.2.1 Total prostate specific antigen test
- 5.2.2 Complex prostate specific antigen test
- 5.2.3 Free prostate specific antigen test
- 5.3 Confirmatory tests
- 5.3.1 Biopsy
- 5.3.2 Trans-rectal ultrasound
- 5.3.3 PCA3Test
Chapter 6 Market Estimates and Forecast, By Application, 2022 - 2035 ($ Mn)
- 6.1 Key trends
- 6.2 Prostate cancer screening
- 6.3 Prostate cancer monitoring
Chapter 7 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)
- 7.1 Key trends
- 7.2 Hospitals
- 7.3 Diagnostic centers
- 7.4 Specialty clinics
- 7.5 Other end users
Chapter 8 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)
- 8.1 Key trends
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
Chapter 9 Company Profiles
- 9.1 Abbott
- 9.2 AdvaCare Pharma
- 9.3 Beckman Coulter
- 9.4 BIOMERIEUX
- 9.5 CTK Biotech
- 9.6 DiaSorin
- 9.7 Fujirebio
- 9.8 Intec
- 9.9 KOELIS
- 9.10 Labcorp
- 9.11 mdxhealth
- 9.12 Myriad Genetics
- 9.13 OPKO Health
- 9.14 Roche
- 9.15 SIEMENS Healthineers
